Xtandi
Showing 1 - 25 of 165
Prostatic Tumors, Castration-Resistant Trial in New York (TVB-2640, Enzalutamide)
Not yet recruiting
- Prostatic Neoplasms, Castration-Resistant
-
New York, New YorkWeill Cornell Medicine/NewYork-Presbyterian Hospital
Feb 23, 2023
Prostate Cancer Trial in Baltimore (DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue)
Not yet recruiting
- Prostate Cancer
- DFMO
- +3 more
-
Baltimore, MarylandJohns Hopkins University: Sidney Kimmel Comprehensive Cancer Cen
Sep 22, 2023
Metastatic Castration-resistant Prostate Cancer Trial in Myrtle Beach (Darolutamide, Enzalutamide, Radium-223)
Terminated
- Metastatic Castration-resistant Prostate Cancer
- Enzalutamide during Lead-in Period
- +5 more
-
Myrtle Beach, South CarolinaResearch Site
Sep 9, 2022
Learn About Novel Hormonal Therapies for Metastatic
Not yet recruiting
- Prostatic Neoplasms
- Novel hormonal therapy
-
New York, New YorkPfizer Inc
Nov 21, 2023
Prostatic Tumors Trial in New York, Myrtle Beach, Houston (ORIC-101, enzalutamide 40 MG oral capsule [Xtandi])
Active, not recruiting
- Prostatic Neoplasms
- ORIC-101
- enzalutamide 40 MG oral capsule [Xtandi]
-
New York, New York
- +2 more
Sep 22, 2022
Learn About Novel Hormonal Therapies in People With Metastatic
Not yet recruiting
- Prostatic Neoplasms
- Novel hormonal therapy
-
New York, New YorkPfizer Inc
Oct 2, 2023
Prostate Cancer Metastatic Trial in Leiden (Enzalutamide, 11C or 18F-Choline PET/CT, Whole body MRI)
Completed
- Prostate Cancer Metastatic
- Enzalutamide
- +3 more
-
Leiden, NetherlandsLeiden University Medical Center
Apr 6, 2022
Prostate Cancer, Prostate Adenocarcinoma Trial in Charlotte (ADT+Docetaxel+Enzalutamide)
Active, not recruiting
- Prostate Cancer
- Prostate Adenocarcinoma
-
Charlotte, North CarolinaLevine Cancer Institute
Jan 12, 2023
Prostate Cancer, Prostate Adenocarcinoma Trial (drug, other, procedure)
Not yet recruiting
- Prostate Cancer
- Prostate Adenocarcinoma
- Relacorilant
- +4 more
- (no location specified)
Feb 2, 2023
Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Boston (Apalutamide
Not yet recruiting
- Prostate Adenocarcinoma
- +2 more
- Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]
- Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan
-
Boston, MassachusettsBeth Israel Deaconess Medical Center
Jan 4, 2023
Prostate Cancer, Metastatic Prostate Cancer Trial in Tampa (Abiraterone, Enzalutamide, Apalutamide)
Recruiting
- Prostate Cancer
- Metastatic Prostate Cancer
- Abiraterone
- +3 more
-
Tampa, FloridaMoffitt Cancer Center
Feb 21, 2023
Medicines Called Enzalutamide and Abiraterone in People With
Not yet recruiting
- Prostatic Neoplasms, Castration-Resistant
- Enzalutamide
- Abiraterone acetate
-
New York, New YorkPfizer Inc
Jul 21, 2023
Metastatic Castration-resistant Prostate Cancer Trial (Pembrolizumab, Enzalutamide)
Completed
- Metastatic Castration-resistant Prostate Cancer
- Pembrolizumab
- Enzalutamide
- (no location specified)
Aug 16, 2022
Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Tumors Trial (MK-5684, Dexamethasone, Fludrocortisone
Not yet recruiting
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Prostatic Neoplasms
- MK-5684
- +6 more
- (no location specified)
Nov 21, 2023
Prostate Cancer Trial in Sacramento (Enzalutamide, Metformin Hydrochloride)
Active, not recruiting
- Prostate Cancer
- Enzalutamide
- Metformin Hydrochloride
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Oct 4, 2022
Prostate Cancer, Castration-resistant Prostate Cancer Trial in São Paulo (Docetaxel, Enzalutamide)
Active, not recruiting
- Prostate Cancer
- Castration-resistant Prostate Cancer
-
São Paulo, SP, BrazilInstituto do Câncer do Estado de São Paulo
Sep 14, 2022
Prostate Cancer Trial run by the National Cancer Institute (NCI) (PROSTVAC-F/TRICOM, PROSTVAC-V/TRICOM, Enzalutamide (Xtandi))
Active, not recruiting
- Prostate Cancer
- PROSTVAC-F/TRICOM
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 18, 2022
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial in Bellinzona, London Borough of Sutton (Enzalutamide 40mg,
Recruiting
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Enzalutamide 40mg
- +4 more
-
Bellinzona, Switzerland
- +1 more
Nov 6, 2023
NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer Trial in Whittier, Lake Mary (Afatinib Oral Tablet,
Recruiting
- NSCLC Harboring NRG1 Fusion
- Metastatic Castration-resistant Prostate Cancer
- Afatinib Oral Tablet
- +3 more
-
Whittier, California
- +1 more
Dec 20, 2022
COVID-19 Infection Trial in Bellinzona (Enzalutamide)
Terminated
- COVID-19 Infection
-
Bellinzona, SwitzerlandOncology Institute of Southern Switzerland (IOSI)
Aug 7, 2022
Metastatic Castration Resistant Prostate Cancer, Prostate Tumors Trial run by the NCI (enzalutamide, CRLX101)
Terminated
- Metastatic Castration Resistant Prostate Cancer
- Prostate Neoplasms
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jun 16, 2022
Prostatic Tumors, Castration-Resistant Trial in Leiden (Patient-specific adaptive therapy, Abiraterone acetate, Enzalutamide)
Recruiting
- Prostatic Neoplasms, Castration-Resistant
- Patient-specific adaptive therapy
- +2 more
-
Camperdown, New South Wales, Australia
- +6 more
Jan 11, 2023